Updates from Syncona and our portfolio companies
Freeline, a biotechnology company focused on developing curative gene therapy for chronic systemic diseases, today announces a new program for Gaucher Disease, an inherited metabolic disorder characterized by the progressive build-up of glucocerebroside in lysosomes throughout the body. Freeline is targeting Type 1 Gaucher Disease, the most common and non-neuronopathic form of the disease.
Freeline is pleased to announce the appointment of Brian M. Silver as Chief Financial Officer and Head of Corporate Development. Brian will be based in New York, as the Company establishes offices in the United States.
Freeline will develop a ‘next-generation’ therapy platform at the Cell and Gene Therapy Catapult’s UK-based large-scale GMP manufacturing centre. Company will further develop proprietary viral vector manufacturing technology for bleeding and other disorders.
Freeline Therapeutics (“Freeline”), a biopharmaceutical company focused on the development of curative gene therapies for bleeding and other debilitating disorders, today announced that Anne Prener has been appointed Chief Executive Officer.